News: Umeå, 13 August 2020. Lipum participate in LSX Nordic Viritual event 1-4 September. LSX is a community of senior life science decision makers where they connect senior life science executives with the capital, intelligence, innovation, and partners the companies need to grow their businesses. “Through these conferences and networking events we have the possibility [...]
Clara Laurell. Foto: Roger Larsson, Hallandsposten News: Umeå, 27 August 2020. Growing up with Juvenile Idiopathic Arthritis Every year, more than 200 Swedish children are diagnosed with Juvenile Idiopathic Arthritis (JIA), also called childhood rheumatism. JIA is a rheumatic disease that affects joints, causes severe pain and reduce the quality of life. Lipums aim is [...]
Lipum is on a steady course towards clinical studies with its candidate for the treatment of juvenile idiopathic arthritis (SOL116). Previous we announced that the cell line was fully developed and was ready for the next step. BioStock has taken the opportunity to talk to one of our founders, Professor Olle Hernell, about the company's [...]
Press release June 25, 2020 Lipum is supported by Horizon 2020, the EU framework program for research and development, and was granted 23 MSEK for the development of a biological pharmaceutical for treatment of chronic inflammatory diseases. In addition to this grant another 25 MSEK was raised in 2019. Now the capital needed to maintain [...]
Aktieägarna i Lipum AB, org. nr. 556813-5999 ("Lipum"), kallas härmed till årsstämma torsdagen den 25 juni 2020, kl. 16:00 på Tvistevägen 48C i Umeå. Aktieägare som önskar delta i stämman ska vara införd i aktieboken per dagen för stämman. Föranmälan senast måndagen den 22 juni 2019 per e-post till investor@lipum.se. Ladda ned kallelsen här »
What effect has elevated levels of our target molecule on human blood? Together with our partner Immuneed we will increase our understanding. Another step towards a novel treatment of inflammatory diseases.
Immuneed is announceing the start of a our cooperation. Behind our project are extensive discussions and planning, which Dr. Pernilla Abrahamsson, Chief Operating Officer at Lipum sees as a cornerstone of successful cooperation. ”Drug development is both time-consuming and expensive, which makes it important for partners to understand one another,” she says. ”Creating a solid [...]
At last our fully humanised antibody and lead candidate SOL-116 will be traveling soon. The production development at Abzena proceeds successfully and according to plan. Downstream processing and quality control have been done and SOL-116 is on its way to Umeå. An enthusiastic team is waiting impatiently to continue with further studies.
At the end of last year, we were able to announce that the cell line had been completed. Recently, another good news was brought, a significant reinforcement to the company's board. BioStock took the opportunity to talk to Lipum's new addition to the boardroom, Dr. Kristian Sandberg, about his thoughts about Lipum and what he [...]
SwedenBIO has opened up a Q&A function on their website. Here, questions can be asked about the Swedish life science industry's role in meeting current challenges. Click here to get to Q&A »